Your session is about to expire
← Back to Search
Cancer Vaccines for Lynch Syndrome
Study Summary
This trial is testing a combination of two vaccines to see if they can prevent cancer in people with Lynch syndrome.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had an organ transplant or have a condition that weakens my immune system.I have HIV with a CD4 count under 540, or I have hepatitis B or C.Your creatinine levels are within the normal range set by the hospital.You have a white blood cell count of at least 3,000 per microliter.It has been over 6 months since my last cancer treatment.I can schedule my COVID vaccines around the study treatment by 2 weeks.It has been over 6 months since my last cancer treatment.I have a history of blood clots that haven't been treated.Your platelet count is at least 100,000 per microliter.Your bilirubin levels are within the normal range for the hospital.Your AST and ALT liver enzyme levels are not higher than 1.5 times the normal limit.Your liver function tests should not be more than 1.5 times the normal level.I haven't taken steroids or immunosuppressants in the last 3 months.You need to have a certain level of white blood cells called neutrophils in your blood.I am mostly active and can care for myself.I am 18 years old or older.You have had allergic reactions to vaccines similar to adenovirus-based vaccines and N-803.You had bad reactions to vaccines made from adenovirus in the past.People with Lynch syndrome as determined by specific criteria.I agree to use birth control during the study.I have a genetic condition linked to colon cancer and a history of colon issues.I still have part of my lower colon or rectum.
- Group 1: Safety phase I (Tri-Ad5)
- Group 2: Safety phase II (Tri-Ad5 , N-803)
- Group 3: Arm I (Tri-Ad5, N-803)
- Group 4: Arm II (placebo)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many locations have been identified to execute this research in the city?
"The medical trial is currently active at 13 different facilities, including UNC Lineberger Comprehensive Cancer Center in Chapel Hill, Northwestern University in Chicago and the University of Arizona Cancer Center - Prevention Research Clinic in Tucson. Other participating sites are also available."
What potential risks or hazards are associated with Vaccine Therapy?
"Vaccine Therapy has been assigned a score of 2, as the second phase of trials have only produced data that suggest it is safe but not yet effective."
Are there any current enrollments for this clinical experiment?
"Per the information hosted on clinicaltrials.gov, this specific trial is no longer accepting participants. Initially published in November of 2022, it was last updated mid-September and has since been closed to recruitment; however, there are over 1300 other studies actively looking for volunteers at present."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger